Sudeep Pharma (BOM:544619) EBIT: ₹1,712 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544619 Sudeep Pharma Ltd BOM:544619
18 GF Score
Price ₹868.55
! 5 Warning Signs
View Full Analysis

What is Sudeep Pharma EBIT?

Sudeep Pharma BOM:544619 -1.10% 18 EBIT is ₹1,712 Mil as of Mar. 2026. GuruFocus rates BOM:544619 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

Sudeep Pharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹630 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,712 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sudeep Pharma's annualized ROC % for the quarter that ended in Mar. 2026 was 18.90%. Sudeep Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 28.94%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sudeep Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 1.74%.

Sudeep Pharma  (BOM:544619) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sudeep Pharma's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=2399.312 * ( 1 - 22.58% )/( (0 + 9828.319)/ 1 )
=1857.5473504/9828.319
=18.90 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11748.765 - 773.99 - ( 1146.456 - max(0, 2019.625 - 6239.66+1146.456))
=9828.319

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Sudeep Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2518.968/( ( (0 + max(0, 0)) + (4524.295 + max(4179.923, 0)) )/ 1 )
=2518.968/( ( 0 + 8704.218 )/ 1 )
=2518.968/8704.218
=28.94 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2275.443 + 2160.465 + 615.644) - (773.99 + 0 + 97.639)
=4179.923

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sudeep Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=1712.026/98606.835
=1.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sudeep Pharma EBIT Related Terms

Sudeep Pharma EBIT Historical Data

* Premium members only.

The historical data trend for Sudeep Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sudeep Pharma EBIT Chart

Sudeep Pharma Annual Data
Trend Mar23 Mar24 Mar25 Mar26
EBIT
893.86 1,778.83 1,875.03 2,335.18

Sudeep Pharma Quarterly Data
Mar23 Mar24 Dec24 Mar25 Jun25 Dec25 Mar26
EBIT Get a 7-Day Free Trial 390.68 585.19 452.82 629.46 629.74

BOM:544619 vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sudeep Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sudeep Pharma EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sudeep Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sudeep Pharma's EV-to-EBIT falls into.


BOM:544619
18GF Score
Sudeep Pharma Ltd BOM:544619
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sudeep Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,712 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹1,712 Mil mean?
Sudeep Pharma (BOM:544619) has a EBIT of ₹1,712 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sudeep Pharma.
Is Sudeep Pharma's EBIT too high?
Sudeep Pharma's current EBIT is ₹1,712 Mil. Overall, Sudeep Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's EBIT compare to ZTS?
Sudeep Pharma's EBIT of ₹1,712 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sudeep Pharma. Sudeep Pharma's current EBIT is ₹1,712 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current EBIT of ₹1,712 Mil. The current EBIT is ₹1,712 Mil. Sudeep Pharma's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current EBIT is ₹1,712 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sudeep Pharma Business Description

Other Exchanges SUDEEPPHRM:India
Address Gotri-Sevasi Road, 601-602, 6th floor, Sears II, East Wing, Towers - 2, Sevasi, Vadodara, GJ, IND, 391101
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
18GF Score

Get the complete analysis for BOM:544619

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹868.55
Price